2016
DOI: 10.1183/13993003.02146-2015
|View full text |Cite
|
Sign up to set email alerts
|

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB

Abstract: No large study has ever evaluated the efficacy, safety and tolerability of meropenem/ clavulanate to treat multidrug-and extensively drug-resistant tuberculosis (MDR-and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR-and XDR-TB cases.Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
63
0
6

Year Published

2016
2016
2022
2022

Publication Types

Select...
7
2

Relationship

3
6

Authors

Journals

citations
Cited by 92 publications
(70 citation statements)
references
References 46 publications
1
63
0
6
Order By: Relevance
“…However, a lack of an active oral formulation and the necessity of combining amoxicillin-clavulanate (to protect it from ß-lactamases) renders these compounds less appealing, even though some appear very active with excellent tolerability and safety. [80][81][82] Linezolid, an oxazolidinone, has demonstrated anti-mycobacterial efficacy and is included in many drug trial regimens; 83 however, its toxicity profile does not allow for its use beyond drug-resistant TB. Sutezolid and delpazolid are two newer generation oxazolidinones in early clinical trials which are hoped to be just as effective as linezolid but less toxic.…”
Section: Repurposed Drugsmentioning
confidence: 99%
“…However, a lack of an active oral formulation and the necessity of combining amoxicillin-clavulanate (to protect it from ß-lactamases) renders these compounds less appealing, even though some appear very active with excellent tolerability and safety. [80][81][82] Linezolid, an oxazolidinone, has demonstrated anti-mycobacterial efficacy and is included in many drug trial regimens; 83 however, its toxicity profile does not allow for its use beyond drug-resistant TB. Sutezolid and delpazolid are two newer generation oxazolidinones in early clinical trials which are hoped to be just as effective as linezolid but less toxic.…”
Section: Repurposed Drugsmentioning
confidence: 99%
“…The potential usefulness of meropenem plus clavulanate or imipenem plus clavulanate has been highlighted, but it is expensive, requires long-term intravenous access, and insufficient clinical evidence of its usefulness or effectiveness exists. 287,288 Use of linezolid, bedaquiline, and delamanid…”
Section: Principles Of Formulating a Treatment Regimen For Mdr And Xdmentioning
confidence: 99%
“…Imipenem/cilastatin and meropenem, combined with clavulanic acid, seem to have a promising activity, while being well tolerated (34)(35)(36)(37). In the direct comparison meropenem performs better than imipenem (37).…”
Section: Which Drugs Might Be Upgradedmentioning
confidence: 99%
“…Imipenem/cilastatin and meropenem, combined with clavulanic acid, seem to have a promising activity, while being well tolerated (34)(35)(36)(37). In the direct comparison meropenem performs better than imipenem (37). Initial clinical experience with ertapenem suggests that it can be a valid drug for the home-care phase of MDR-TB treatment, as it can be administered intramuscularly once a day (38).…”
Section: Which Drugs Might Be Upgradedmentioning
confidence: 99%